Basking Biosciences

Prescription Drugs · Biotechnology

Overview

Advancing reversible therapies targeting von Willebrand Factor for safer treatment of acute thrombotic conditions. Precision control when seconds matter.

Financials

Total raised
$59.1M
Latest round
Venture - Series Unknown
Funding rounds
3
Funding rounds
Round Announced Amount
Venture - Series Unknown 2023 $55M Details
Venture - Series Unknown 2020 $1.9M Details
Grant 2020 $2.2M Details

People

Richard Shea
Executive Officer, Director
SEC Form D
Julia Owens
Executive Officer, Director
SEC Form D
Ryan Helon
Director
SEC Form D
Thomas Needham
Director
SEC Form D
Dan Myers
Director
SEC Form D
Shahid Nimjee
Director
SEC Form D
Bruce Sullenger
Director
SEC Form D
Hannah Chang
Director
SEC Form D
Aiden Aceves
Director
SEC Form D
Steve Gillis
Director
SEC Form D
David Adair
Director
SEC Form D
Ari Nowacek
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Connections

List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors3
Broadview VenturesVia a fund
47 portfolio companies: Yelling Mule, Xiimedical, Zzbiotech and 44 more
ARCH Venture PartnersVia a fund
126 portfolio companies: Vilya, Xaira Therapeutics, Vizgen and 123 more
Insight PartnersVia a fund
812 portfolio companies
Report a mistake

News

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Cary United States
HQ
200-500 est. staff